Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ultra-short all-oral regimen withdrawal trial for fluoroquinolone-sensitive multidrug-resistant tuberculosis
ChiCTR2000041491Phase 3Recruiting
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Jan 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bedaquiline, linezolid, moxifloxacin and d-cycloserine in multidrug-resistant tuberculosis (MDR-TB) (2 arms), sponsored by Shenzhen Third People's Hospital. Primary endpoint: Unfavorable outcome. Started Jan 2021; status: recruiting.
02
Drugs
bedaquilinelinezolidmoxifloxacind-cycloserine
03
Conditions
multidrug-resistant tuberculosis (MDR-TB)
Beyond the preview
Go deeper on ChiCTR2000041491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000041491.